We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current 0R2M market cap is 32.05B. The company's latest EPS is USD 40.8302 and P/E is 17.11.
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 8.78B | 16.12B | 12.26B | 13.12B | 14.2B |
| Operating Income | 3.58B | 8.95B | 4.74B | 4.05B | 3.99B |
| Net Income | 3.51B | 8.08B | 4.34B | 3.95B | 4.41B |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 17.16B | 25.43B | 29.21B | 33.08B | 37.76B |
| Total Liabilities | 6.14B | 6.67B | 6.55B | 7.11B | 8.41B |
| Total Equity | 11.03B | 18.77B | 22.66B | 25.97B | 29.35B |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 2.62B | 7.08B | 5.01B | 4.59B | 4.42B |
| Investing | -70.6M | -5.38B | -3.78B | -3.19B | -2.47B |
| Financing | -1.97B | -1.01B | -1.01B | -1.79B | -2.2B |
| Market Cap | 32.05B |
| Price to Earnings Ratio | 17.11 |
| Price to Sales Ratio | 5.32 |
| Price to Cash Ratio | 30.35 |
| Price to Book Ratio | 2.57 |
| Dividend Yield | - |
| Shares Outstanding | 108.07M |
| Average Volume (1 week) | 177 |
| Average Volume (1 Month) | 1.55k |
| 52 Week Change | 0.00% |
| 52 Week High | 296.60 |
| 52 Week Low | 296.60 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Regeneron Pharmaceuticals Inc |
| Address |
28 liberty street new york, new york 10005 |
| Website | https://www.regeneron.com |
| Industry | health care diversified (H) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
